trending Market Intelligence /marketintelligence/en/news-insights/trending/h2WsT3hVF1_saXzQ8TNvuA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Epizyme seeks accelerated US FDA approval for cancer drug

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Epizyme seeks accelerated US FDA approval for cancer drug

Epizyme Inc. is seeking accelerated U.S. Food and Drug Administration approval for its drug tazemetostat as a treatment for a certain kind of blood cancer.

The Cambridge, Mass.-based drugmaker filed a new drug application for tazemetostat for treating patients with relapsed or refractory follicular lymphoma — a cancer that affects white blood cells — and who have received at least two prior lines of systemic therapy.

The lymphoma can be with or without EZH2 activating mutations.

The application is based on a mid-stage study of the drug for patients with the disease, where the therapy showed clinical benefit and was also well-tolerated among follicular lymphoma patients.

The submission also follows a pre-new drug application meeting with the U.S. regulator in October, where the agency indicated it considered the proposed clinical package as sufficient for accelerated approval.

To support a full approval for the indication, Epizyme is conducting a single, global, randomized trial evaluating tazemetostat with Revlimid and Rituxan for follicular lymphoma patients as a second-line or later treatment.

The U.S. FDA is expected to decide whether or not to accept the submission for review within 60 days.

A panel of outside advisers to the U.S. FDA also recently voted unanimously to approve tazemetostat for treating epithelioid sarcoma.